|
| Status |
Public on Sep 21, 2020 |
| Title |
AML17 |
| Sample type |
RNA |
| |
|
| Source name |
Bone Marrow
|
| Organism |
Homo sapiens |
| Characteristics |
tp53 status: Mutated
disease state at sampling: Diagnosis
|
| Treatment protocol |
At time of initial diagnosis.
|
| Growth protocol |
Human Samples
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA extraction was carried out using Qiagen RNeasy RNA isolation kits. Quantitation of RNA was performed using Nanodrop and Qubit RNA high sensitivity assay.
|
| Label |
Nanostring bar coding
|
| Label protocol |
RNA ispecies were identified and counted using the NanoString IO 360 Panel.
|
| |
|
| Hybridization protocol |
Hybridisation was performed in a PCR for 20 hours at 65°C.
|
| Scan protocol |
Scanned with NanoString Digital analyser with 555 FOV
|
| Description |
IO 360 panel
|
| Data processing |
Data was normalised using the nSolver software, version 4.0.
|
| |
|
| Submission date |
Mar 02, 2020 |
| Last update date |
Sep 21, 2020 |
| Contact name |
Sergio Rutella |
| E-mail(s) |
sergio.rutella@ntu.ac.uk
|
| Phone |
+441158483205
|
| Organization name |
Nottingham Trent University
|
| Department |
John van Geest Cancer Research Centre
|
| Lab |
Cancer Immunotherapy
|
| Street address |
Clifton Campus
|
| City |
Nottingham |
| ZIP/Postal code |
NG11 8NS |
| Country |
United Kingdom |
| |
|
| Platform ID |
GPL27956 |
| Series (1) |
| GSE146204 |
TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia |
|
